Trevi Therapeutics (TRVI) Stock Forecast: StockMap's 2-Week Call
TRVI stock forecast: StockMap's model leans Underperform on Trevi Therapeutics for the two weeks after the Nov 19 close, toward TRVI trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 1 of 3 two-week windows on TRVI since Oct 2; by chance, a call on the same dates was right 40% of the time.
Trevi Therapeutics last closed at $13.72, +1.55% on the session.
Against the IVW growth benchmark the position is +3.88% over the forecast window.
Trevi Therapeutics' market cap is $1.96B as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -30 (too close to call).
Where TRVI sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 5 bullish and 10 bearish.
Agreement across those insights is 67%.
21 daily calls for TRVI so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Trevi Therapeutics in the 26th percentile on return on equity, where 100 is best.
Trevi Therapeutics is classified under Health Care / Pharmaceuticals.
StockMap tracks Trevi Therapeutics as the 43rd largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite Trevi Therapeutics ranks 68th of 153 in the group, against a group median of -0.36.